New published data have demonstrated positive monotherapy results for misetionamide as well as synergistic activity with PARP inhibitors (PARPis) and bevacizumab antineoplastic in ovarian cancer. Misetionamide is a tumour cell selective small molecule drug that is broadly active in multiple cancer models. Misetionamide’s inhibition… Read More
AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as first-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch repair proficient… Read More
New findings suggest PARP inhibitor drugs, used to treat cancer patients who have an altered BRCA1 or BRCA2 gene, may also be effective for patients which have changes in the SF3B1 gene. If further research supports these findings, there is the potential that existing PARP inhibitor… Read More
Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has acquired Theragnostics, a UK-based private biopharmaceutical company engaged in the development of radio-labelled PARP inhibitors for the diagnosis and treatment of tumours. The acquisition provides Ariceum with an… Read More
